A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis

Cancer Cell

Volumn 28, Issue 5, 2015, Pages 599-609

  Schnepp, Robert W ^a   Khurana, Priya ^a   Attiyeh, Edward F ^a,b   Raman, Pichai ^a   Chodosh, Sara E ^a   Oldridge, Derek A ^a   Gagliardi, Maria E ^a   Conkrite, Karina L ^a   Asgharzadeh, Shahab ^c   Seeger, Robert C ^c   Madison, Blair B ^d   Rustgi, Anil K ^b,e   Maris, John M ^a,b,e   Diskin, Sharon J ^a,b,e  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; BINDING PROTEIN; LIN28B PROTEIN; MESSENGER RNA; ONCOPROTEIN; RAN BINDING PROTEIN 2; RAN PROTEIN; UNCLASSIFIED DRUG; AURKA PROTEIN, HUMAN; CHAPERONE; LIN28B PROTEIN, HUMAN; MICRORNA; MIRNLET7 MICRORNA, HUMAN; MYCN PROTEIN, HUMAN; N MYC PROTO ONCOGENE PROTEIN; NUCLEAR PROTEIN; NUCLEOPORIN; RAN PROTEIN, HUMAN; RAN-BINDING PROTEIN 2; RNA BINDING PROTEIN;

ARTICLE; CARCINOGENESIS; CHROMOSOME 12Q; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIN28B GENE; NEUROBLASTOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN RNA BINDING; RAN GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; CHILD; CHROMOSOME 12; COPY NUMBER VARIATION; DNA MICROARRAY; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

AURORA KINASE A; BLOTTING, WESTERN; CARCINOGENESIS; CELL LINE, TUMOR; CHILD; CHROMOSOMES, HUMAN, PAIR 12; DNA COPY NUMBER VARIATIONS; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MICRORNAS; MOLECULAR CHAPERONES; N-MYC PROTO-ONCOGENE PROTEIN; NEUROBLASTOMA; NUCLEAR PORE COMPLEX PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS; RAN GTP-BINDING PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84946548440     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.09.012     Document Type: Article

References (66)

1. Abe H., Kamai T., Shirataki H., Oyama T., Arai K., Yoshida K. High expression of Ran GTPase is associated with local invasion and metastasis of human clear cell renal cell carcinoma. Int. J. Cancer 2008, 122:2391-2397.
2. Barrès V., Ouellet V., Lafontaine J., Tonin P.N., Provencher D.M., Mes-Masson A.M. An essential role for Ran GTPase in epithelial ovarian cancer cell survival. Mol. Cancer 2010, 9:272.
3. Beroukhim R., Getz G., Nghiemphu L., Barretina J., Hsueh T., Linhart D., Vivanco I., Lee J.C., Huang J.H., Alexander S., et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 2007, 104:20007-20012.
4. Betel D., Wilson M., Gabow A., Marks D.S., Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008, 36:D149-D153.
5. Bosse K.R., Diskin S.J., Cole K.A., Wood A.C., Schnepp R.W., Norris G., Nguyen B., Jagannathan J., Laquaglia M., Winter C., et al. Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity. Cancer Res. 2012, 72:2068-2078.
6. Boyerinas B., Park S.M., Hau A., Murmann A.E., Peter M.E. The role of let-7 in cell differentiation and cancer. Endocr. Relat. Cancer 2010, 17:F19-F36.
7. Bresler S.C., Weiser D.A., Huwe P.J., Park J.H., Krytska K., Ryles H., Laudenslager M., Rappaport E.F., Wood A.C., McGrady P.W., et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014, 26:682-694.
8. Capasso M., Devoto M., Hou C., Asgharzadeh S., Glessner J.T., Attiyeh E.F., Mosse Y.P., Kim C., Diskin S.J., Cole K.A., et al. Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat. Genet. 2009, 41:718-723.
9. Cheung N.K., Zhang J., Lu C., Parker M., Bahrami A., Tickoo S.K., Heguy A., Pappo A.S., Federico S., Dalton J., et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012, 307:1062-1071.
10. Cho J., Chang H., Kwon S.C., Kim B., Kim Y., Choe J., Ha M., Kim Y.K., Kim V.N. LIN28A is a suppressor of ER-associated translation in embryonic stem cells. Cell 2012, 151:765-777.
11. Clarke P.R., Zhang C. Spatial and temporal coordination of mitosis by Ran GTPase. Nat. Rev. Mol. Cell Biol. 2008, 9:464-477.
12. Cole K.A., Huggins J., Laquaglia M., Hulderman C.E., Russell M.R., Bosse K., Diskin S.J., Attiyeh E.F., Sennett R., Norris G., et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc. Natl. Acad. Sci. USA 2011, 108:3336-3341.
13. Delphin C., Guan T., Melchior F., Gerace L. RanGTP targets p97 to RanBP2, a filamentous protein localized at the cytoplasmic periphery of the nuclear pore complex. Mol. Biol. Cell 1997, 8:2379-2390.
14. Deng L., Lu Y., Zhao X., Sun Y., Shi Y., Fan H., Liu C., Zhou J., Nie Y., Wu K., et al. Ran GTPase protein promotes human pancreatic cancer proliferation by deregulating the expression of Survivin and cell cycle proteins. Biochem. Biophys. Res. Commun. 2013, 440:322-329.
15. Diskin S.J., Capasso M., Schnepp R.W., Cole K.A., Attiyeh E.F., Hou C., Diamond M., Carpenter E.L., Winter C., Lee H., et al. Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat. Genet. 2012, 44:1126-1130.
16. Esquela-Kerscher A., Trang P., Wiggins J.F., Patrawala L., Cheng A., Ford L., Weidhaas J.B., Brown D., Bader A.G., Slack F.J. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008, 7:759-764.
17. Guvenc H., Pavlyukov M.S., Joshi K., Kurt H., Banasavadi-Siddegowda Y.K., Mao P., Hong C., Yamada R., Kwon C.H., Bhasin D., et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin. Cancer Res. 2013, 19:631-642.
18. Hafner M., Max K.E., Bandaru P., Morozov P., Gerstberger S., Brown M., Molina H., Tuschl T. Identification of mRNAs bound and regulated by human LIN28 proteins and molecular requirements for RNA recognition. RNA 2013, 19:613-626.
19. Helland Å., Anglesio M.S., George J., Cowin P.A., Johnstone C.N., House C.M., Sheppard K.E., Etemadmoghadam D., Melnyk N., Rustgi A.K., et al. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS ONE 2011, 6:e18064. Australian Ovarian Cancer Study Group.
20. Keene J.D., Komisarow J.M., Friedersdorf M.B. RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. Nat. Protoc. 2006, 1:302-307.
21. King C.E., Cuatrecasas M., Castells A., Sepulveda A.R., Lee J.S., Rustgi A.K. LIN28B promotes colon cancer progression and metastasis. Cancer Res. 2011, 71:4260-4268.
22. King C.E., Wang L., Winograd R., Madison B.B., Mongroo P.S., Johnstone C.N., Rustgi A.K. LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene 2011, 30:4185-4193.
23. Krek A., Grün D., Poy M.N., Wolf R., Rosenberg L., Epstein E.J., MacMenamin P., da Piedade I., Gunsalus K.C., Stoffel M., Rajewsky N. Combinatorial microRNA target predictions. Nat. Genet. 2005, 37:495-500.
24. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
25. Liu F., Zhang X., Weisberg E., Chen S., Hur W., Wu H., Zhao Z., Wang W., Mao M., Cai C., et al. Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem. Biol. 2013, 8:1423-1428.
26. Madison B.B., Liu Q., Zhong X., Hahn C.M., Lin N., Emmett M.J., Stanger B.Z., Lee J.S., Rustgi A.K. LIN28B promotes growth and tumorigenesis of the intestinal epithelium via Let-7. Genes Dev. 2013, 27:2233-2245.
27. Maris J.M. Recent advances in neuroblastoma. N. Engl. J. Med. 2010, 362:2202-2211.
28. Maris J.M., Morton C.L., Gorlick R., Kolb E.A., Lock R., Carol H., Keir S.T., Reynolds C.P., Kang M.H., Wu J., et al. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr. Blood Cancer 2010, 55:26-34.
29. Melchior F., Guan T., Yokoyama N., Nishimoto T., Gerace L. GTP hydrolysis by Ran occurs at the nuclear pore complex in an early step of protein import. J. Cell Biol. 1995, 131:571-581.
30. Molenaar J.J., Domingo-Fernández R., Ebus M.E., Lindner S., Koster J., Drabek K., Mestdagh P., van Sluis P., Valentijn L.J., van Nes J., et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat. Genet. 2012, 44:1199-1206.
31. Molenaar J.J., Koster J., Zwijnenburg D.A., van Sluis P., Valentijn L.J., van der Ploeg I., Hamdi M., van Nes J., Westerman B.A., van Arkel J., et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 2012, 483:589-593.
32. Morozova O., Vojvodic M., Grinshtein N., Hansford L.M., Blakely K.M., Maslova A., Hirst M., Cezard T., Morin R.D., Moore R., et al. System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clin. Cancer Res. 2010, 16:4572-4582.
33. Mosse Y.P., Lipsitz E., Fox E., Teachey D.T., Maris J.M., Weigel B., Adamson P.C., Ingle M.A., Ahern C.H., Blaney S.M. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin. Cancer Res. 2012, 18:6058-6064.
34. Murray M.J., Saini H.K., Siegler C.A., Hanning J.E., Barker E.M., van Dongen S., Ward D.M., Raby K.L., Groves I.J., Scarpini C.G., et al. LIN28 Expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels. Cancer Res. 2013, 73:4872-4884. CCLG.
35. Nguyen K.T., Holloway M.P., Altura R.A. The CRM1 nuclear export protein in normal development and disease. Int. J. Biochem. Mol. Biol. 2012, 3:137-151.
36. Nguyen L.H., Robinton D.A., Seligson M.T., Wu L., Li L., Rakheja D., Comerford S.A., Ramezani S., Sun X., Parikh M.S., et al. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell 2014, 26:248-261.
37. Oberthuer A., Hero B., Berthold F., Juraeva D., Faldum A., Kahlert Y., Asgharzadeh S., Seeger R., Scaruffi P., Tonini G.P., et al. Prognostic impact of gene expression-based classification for neuroblastoma. J. Clin. Oncol. 2010, 28:3506-3515.
38. Oh J.S., Kim J.J., Byun J.Y., Kim I.A. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras. Int. J. Radiat. Oncol. Biol. Phys. 2010, 76:5-8.
39. Otto T., Horn S., Brockmann M., Eilers U., Schüttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
40. Park S.M., Shell S., Radjabi A.R., Schickel R., Feig C., Boyerinas B., Dinulescu D.M., Lengyel E., Peter M.E. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007, 6:2585-2590.
41. Patil H., Saha A., Senda E., Cho K.I., Haque M., Yu M., Qiu S., Yoon D., Hao Y., Peachey N.S., Ferreira P.A. Selective impairment of a subset of Ran-GTP-binding domains of ran-binding protein 2 (Ranbp2) suffices to recapitulate the degeneration of the retinal pigment epithelium (RPE) triggered by Ranbp2 ablation. J. Biol. Chem. 2014, 289:29767-29789.
42. Peng S., Chen L.L., Lei X.X., Yang L., Lin H., Carmichael G.G., Huang Y. Genome-wide studies reveal that Lin28 enhances the translation of genes important for growth and survival of human embryonic stem cells. Stem Cells 2011, 29:496-504.
43. Piskounova E., Polytarchou C., Thornton J.E., LaPierre R.J., Pothoulakis C., Hagan J.P., Iliopoulos D., Gregory R.I. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 2011, 147:1066-1079.
44. Pugh T.J., Morozova O., Attiyeh E.F., Asgharzadeh S., Wei J.S., Auclair D., Carter S.L., Cibulskis K., Hanna M., Kiezun A., et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 2013, 45:279-284.
45. Puissant A., Frumm S.M., Alexe G., Bassil C.F., Qi J., Chanthery Y.H., Nekritz E.A., Zeid R., Gustafson W.C., Greninger P., et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3:308-323.
46. Sampson V.B., Rong N.H., Han J., Yang Q., Aris V., Soteropoulos P., Petrelli N.J., Dunn S.P., Krueger L.J. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res. 2007, 67:9762-9770.
47. Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X., Blackford A., Parmigiani G., Diaz L.A., Papadopoulos N., et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 2013, 45:12-17.
48. Shyh-Chang N., Zhu H., Yvanka de Soysa T., Shinoda G., Seligson M.T., Tsanov K.M., Nguyen L., Asara J.M., Cantley L.C., Daley G.Q. Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell 2013, 155:778-792.
49. Trieselmann N., Armstrong S., Rauw J., Wilde A. Ran modulates spindle assembly by regulating a subset of TPX2 and Kid activities including Aurora A activation. J. Cell Sci. 2003, 116:4791-4798.
50. Tsai M.Y., Wiese C., Cao K., Martin O., Donovan P., Ruderman J., Prigent C., Zheng Y. A Ran signalling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat. Cell Biol. 2003, 5:242-248.
51. Urbach A., Yermalovich A., Zhang J., Spina C.S., Zhu H., Perez-Atayde A.R., Shukrun R., Charlton J., Sebire N., Mifsud W., et al. Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev. 2014, 28:971-982.
52. Valentijn L.J., Koster J., Haneveld F., Aissa R.A., van Sluis P., Broekmans M.E., Molenaar J.J., van Nes J., Versteeg R. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. USA 2012, 109:19190-19195.
53. Viswanathan S.R., Daley G.Q., Gregory R.I. Selective blockade of microRNA processing by Lin28. Science 2008, 320:97-100.
54. Viswanathan S.R., Powers J.T., Einhorn W., Hoshida Y., Ng T.L., Toffanin S., O'Sullivan M., Lu J., Phillips L.A., Lockhart V.L., et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 2009, 41:843-848.
55. Wang Q., Diskin S., Rappaport E., Attiyeh E., Mosse Y., Shue D., Seiser E., Jagannathan J., Shusterman S., Bansal M., et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006, 66:6050-6062.
56. Wang Y.C., Chen Y.L., Yuan R.H., Pan H.W., Yang W.C., Hsu H.C., Jeng Y.M. Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis 2010, 31:1516-1522.
57. Wang K., Diskin S.J., Zhang H., Attiyeh E.F., Winter C., Hou C., Schnepp R.W., Diamond M., Bosse K., Mayes P.A., et al. Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature 2011, 469:216-220.
58. Wang L., Yuan C., Lv K., Xie S., Fu P., Liu X., Chen Y., Qin C., Deng W., Hu W. Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and Let-7 signaling. PLoS ONE 2013, 8:e67373.
59. Wilbert M.L., Huelga S.C., Kapeli K., Stark T.J., Liang T.Y., Chen S.X., Yan B.Y., Nathanson J.L., Hutt K.R., Lovci M.T., et al. LIN28 binds messenger RNAs at GGAGA motifs and regulates splicing factor abundance. Mol. Cell 2012, 48:195-206.
60. Wolf M., Korja M., Karhu R., Edgren H., Kilpinen S., Ojala K., Mousses S., Kallioniemi A., Haapasalo H. Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer 2010, 10:181.
61. Wyce A., Ganji G., Smitheman K.N., Chung C.W., Korenchuk S., Bai Y., Barbash O., Le B., Craggs P.D., McCabe M.T., et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS ONE 2013, 8:e72967.
62. Xia F., Lee C.W., Altieri D.C. Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res. 2008, 68:1826-1833.
63. Yaseen N.R., Blobel G. Two distinct classes of Ran-binding sites on the nucleoporin Nup-358. Proc. Natl. Acad. Sci. USA 1999, 96:5516-5521.
64. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
65. Zhang F., Yang Z., Cao M., Xu Y., Li J., Chen X., Gao Z., Xin J., Zhou S., Zhou Z., et al. MiR-203 suppresses tumor growth and invasion and down-regulates MiR-21 expression through repressing Ran in esophageal cancer. Cancer Lett. 2014, 342:121-129.
66. Zhu H., Shyh-Chang N., Segrè A.V., Shinoda G., Shah S.P., Einhorn W.S., Takeuchi A., Engreitz J.M., Hagan J.P., Kharas M.G., et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 2011, 147:81-94. DIAGRAM Consortium, MAGIC InvestigatorsMAGIC Investigators.